Heidelberg Pharma AG

Heidelberg Pharma and Huadong Medicine have signed an expanded research agreement to jointly develop new antibody‑drug conjugates (ADCs). The partnership covers up to six target molecules, use of Heidelberg Pharma’s ATAC technology, and new toxin payloads, and enables bispecific/multispecific ADCs with two drug payloads. Ownership rights to development candidates will be split according to the partners’ contributions, with the goal of improving the efficacy and safety of new therapies. » Más en finanzen.net